首页> 外文期刊>Drug delivery. >Design of novel miconazole nitrate transdermal films based on Eudragit RS100 and HPMC hybrids: preparation, physical characterization, in vitro and ex vivo studies
【24h】

Design of novel miconazole nitrate transdermal films based on Eudragit RS100 and HPMC hybrids: preparation, physical characterization, in vitro and ex vivo studies

机译:基于Eudragit RS100和HPMC杂化物的新型硝酸咪康唑透皮膜的设计:制备,物理表征,体外和离体研究

获取原文
       

摘要

The objective of this study was to formulate and evaluate transdermal films containing miconazole nitrate (MN), a poorly water-soluble imidazole antifungal agent, with a view to enhancing its delivery across intact skin. Transdermal films of MN were formulated by solvent casting technique using admixtures of film-forming polymers – Eudragit RS100 and hydroxypropylmethylcellulose (HPMC) (2:8, 4:6, 5:5, 6:4 and 8:2) with polyethylene glycol 8000 (plasticizer and permeation enhancer) and Tween 80 (mobile surfactant). The films were evaluated for weight uniformity, folding endurance, thickness, moisture loss and uptake, bioadhesive strength, drug content, skin irritation on rabbits and time-resolved stability. The ex vivo release of MN from the films was carried out using a modified Franz diffusion apparatus while the microbiological evaluation was conducted using a clinical isolate of Candida albicans. Overall results indicate that films made with two portions of Eudragit RS100 and eight portions of HPMC (batch T-1) had the least weight variation (57.33?±?0.27?mg), folding endurance (307.90?±?4.17), moisture uptake (1.37?±?0.28%) and thickness (145.9?±?2.08?μm), but highest drug content (97.50?±?2.43%) and bioadhesive strength (81.40?±?2.03?dyne/cm2), best bioactivity and in vitro skin permeation through rat skin with highest permeation flux (5.161?μg/cm2?h) and permeation coefficient (1.032?×?10?6?cm/h) compared to all other formulations. This study has established that transdermal films based on 2:8 admixtures of Eudragit RS100 and HPMC could offer a promising approach for the treatment of skin infections caused by MN-susceptible fungi.
机译:这项研究的目的是配制和评估含有硝酸咪康唑(MN)(一种水溶性差的咪唑类抗真菌剂)的透皮薄膜,以增强其在完整皮肤上的递送。通过溶剂流延技术,使用成膜聚合物Eudragit RS100和羟丙基甲基纤维素(HPMC)(2:8、4:6、5:5、6:4和8:2)与聚乙二醇8000的混合物配制MN的透皮薄膜(增塑剂和渗透促进剂)和Tween 80(流动表面活性剂)。评价该膜的重量均匀性,耐折性,厚度,水分损失和摄取,生物粘附强度,药物含量,对兔子的皮肤刺激性和时间分辨的稳定性。使用改良的Franz扩散装置从薄膜中离体释放MN,同时使用白色念珠菌临床分离株进行微生物评估。总体结果表明,由两份Eudragit RS100和八份HPMC(批次T-1)制成的薄膜具有最小的重量变化(57.33?±?0.27?mg),耐折性(307.90?±?4.17),吸湿性(1.37±±0.28%)和厚度(145.9±±2.08μm),但是最高的药物含量(97.50±±2.43%)和生物粘附强度(81.40±±2.03dyne / cm 2 < / sup>),最佳的生物活性和通过大鼠皮肤的体外皮肤渗透,具有最高的渗透通量(5.161?g / cm 2 ?h)和渗透系数(1.032?×?10 ?6) ? cm / h)。这项研究已经确定,基于Eudragit RS100和HPMC 2:8混合物的透皮薄膜可以为治疗由MN易感真菌引起的皮肤感染提供有前途的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号